Unexpected Bone Formation Produced by RANKL Blockade
- 1 October 2017
- journal article
- review article
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 28 (10) , 695-704
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- Stimulation of Bone Formation in Cortical Bone of Mice Treated with a Receptor Activator of Nuclear Factor-κB Ligand (RANKL)-binding Peptide That Possesses Osteoclastogenesis Inhibitory ActivityJournal of Biological Chemistry, 2013
- Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populationsBone, 2012
- Osteocyte RANKL: New insights into the control of bone remodelingJournal of Bone and Mineral Research, 2012
- Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extensionJournal of Bone and Mineral Research, 2011
- Matrix-embedded cells control osteoclast formationNature Medicine, 2011
- Osteoporosis: now and the futureThe Lancet, 2011
- Zinc Finger Protein 467 Is a Novel Regulator of Osteoblast and Adipocyte CommitmentJournal of Biological Chemistry, 2011
- Denosumab for Prevention of Fractures in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2009
- Functions of RANKL/RANK/OPG in bone modeling and remodelingArchives of Biochemistry and Biophysics, 2008
- Osteoclast differentiation and activationNature, 2003